🇺🇸 FDA
Patent

US 11760764

Methods and compositions for targeting PD-L1

granted A61PA61P31/20A61P35/00

Quick answer

US patent 11760764 (Methods and compositions for targeting PD-L1) held by Aligos Therapeutics, Inc. expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aligos Therapeutics, Inc.
Grant date
Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P31/20, A61P35/00